Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial - PubMed (original) (raw)

Clinical Trial

. 1992 Aug-Dec;21(1-3):109-20.

doi: 10.1007/BF02789482.

Affiliations

• PMID: 1285323
• DOI: 10.1007/BF02789482

Clinical Trial

Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial

S K Sharma et al. Cell Biophys. 1992 Aug-Dec.

Abstract

The human immune response to monoclonal antibody-enzyme conjugates has been studied in patients included in the pilot clinical trial of ADEPT. Each patient received murine monoclonal anti-CEA antibody fragments (A5B7-F(ab')2, conjugated to bacterial enzyme, carboxypeptidase G2 (CPG2) followed by a galactosylated monoclonal anti-CPG2 antibody (SB43), 36-48 h after the conjugate. Some patients were also given a dose of 131I-labeled conjugate (4-8 mg, 7-15 mCi) for blood clearance and gamma camera image studies. All patients studied developed human antimouse antibodies (HAMA) and anti-CPG2 antibodies within 10 d after a single course of treatment with the conjugate. In most cases, IgM response was detected at 7 d after the conjugate followed by the IgG response 14 d later. In one patient, HAMA and anti-CPG2 antibodies of the IgG type could still be detected at 10 mo after treatment. Anti-CPG2 antibodies in serum of one patient were found to inhibit CPG2 activity in vitro. Generation of neutralizing antibodies limits the use of repeat cycles of ADEPT in patients. Use of immunosuppressive agents may allow a useful time window for several ADEPT cycle treatments by delaying the appearance of HAMA and anti-CPG2 antibodies. Patients given cyclosporin A before and during ADEPT are currently being studied for HAMA and anti-CPG2 response.

PubMed Disclaimer

Similar articles

• Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
  Sharma SK, Boden JA, Springer CJ, Burke PJ, Bagshawe KD. Sharma SK, et al. Cell Biophys. 1994;24-25:219-28. doi: 10.1007/BF02789232. Cell Biophys. 1994. PMID: 7736526
• Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
  Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, Melton RG, Sherwood RF. Sharma SK, et al. Cancer. 1994 Feb 1;73(3 Suppl):1114-20. doi: 10.1002/1097-0142(19940201)73:3+<1114::aid-cncr2820731352>3.0.co;2-l. Cancer. 1994. PMID: 8306255
• Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
  Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D. Webley SD, et al. Br J Cancer. 2001 Jun 15;84(12):1671-6. doi: 10.1054/bjoc.2001.1843. Br J Cancer. 2001. PMID: 11401322 Free PMC article.
• Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
  Springer CJ, Niculescu-Duvaz I. Springer CJ, et al. Anticancer Drug Des. 1995 Jul;10(5):361-72. Anticancer Drug Des. 1995. PMID: 7639927 Review.
• Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy.
  Moradbeygi F, Ghasemi Y, Farmani AR, Hemmati S. Moradbeygi F, et al. Biomed Pharmacother. 2023 Oct;166:115292. doi: 10.1016/j.biopha.2023.115292. Epub 2023 Aug 12. Biomed Pharmacother. 2023. PMID: 37579696 Review.

Cited by

• Identification of a novel Baeyer-Villiger monooxygenase from Acinetobacter radioresistens: close relationship to the Mycobacterium tuberculosis prodrug activator EtaA.
  Minerdi D, Zgrablic I, Sadeghi SJ, Gilardi G. Minerdi D, et al. Microb Biotechnol. 2012 Nov;5(6):700-16. doi: 10.1111/j.1751-7915.2012.00356.x. Epub 2012 Aug 2. Microb Biotechnol. 2012. PMID: 22862894 Free PMC article.
• A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
  de Graaf M, Boven E, Oosterhoff D, van der Meulen-Muileman IH, Huls GA, Gerritsen WR, Haisma HJ, Pinedo HM. de Graaf M, et al. Br J Cancer. 2002 Mar 4;86(5):811-8. doi: 10.1038/sj.bjc.6600143. Br J Cancer. 2002. PMID: 11875747 Free PMC article.
• Bringing enzymes to the proximity party.
  Tender GS, Bertozzi CR. Tender GS, et al. RSC Chem Biol. 2023 Sep 29;4(12):986-1002. doi: 10.1039/d3cb00084b. eCollection 2023 Nov 29. RSC Chem Biol. 2023. PMID: 38033727 Free PMC article. Review.
• Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
  Sharma SK, Boden JA, Springer CJ, Burke PJ, Bagshawe KD. Sharma SK, et al. Cell Biophys. 1994;24-25:219-28. doi: 10.1007/BF02789232. Cell Biophys. 1994. PMID: 7736526
• Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
  Aldughaim MS, Alsaffar F, Barker MD. Aldughaim MS, et al. Molecules. 2021 Jan 25;26(3):625. doi: 10.3390/molecules26030625. Molecules. 2021. PMID: 33504102 Free PMC article.

References

1. 1. J Antibiot (Tokyo). 1987 Sep;40(9):1256-65 - PubMed
2. 1. J Med Chem. 1990 Feb;33(2):677-81 - PubMed
3. 1. Br J Cancer. 1987 Nov;56(5):531-2 - PubMed
4. 1. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842-6 - PubMed
5. 1. J Immunol. 1985 Aug;135(2):1530-5 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database